Literature DB >> 27919586

Practical management of adverse events related to apomorphine therapy.

Roongroj Bhidayasiri1, Pedro J Garcia Ruiz2, Tove Henriksen3.   

Abstract

The potential for adverse events is often cited as a barrier to the use of subcutaneous apomorphine therapy (intermittent injections and continuous infusion) in the management of Parkinson's disease. However, with proactive management most adverse effects are manageable if reported and tackled early enough. As such, proper clinician and patient awareness of the potential adverse effects is important to minimize their impact on the overall clinical utility of this efficacious antiparkinsonian agent. In this paper, we review the key local and systemic adverse effects reported during apomorphine titration, initiation and long-term treatment, and discuss practical management strategies.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adverse events; Apomorphine; Safety; Tolerability

Mesh:

Substances:

Year:  2016        PMID: 27919586     DOI: 10.1016/j.parkreldis.2016.11.017

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  9 in total

1.  A Novel Method of Treating Apomorphine-Induced Subcutaneous Nodules.

Authors:  Sabela Novo Ponte; Celia García Malo; Maria Rosario Blasco Quílez; Pilar Sánchez Alonso
Journal:  Mov Disord Clin Pract       Date:  2019-11-17

2.  Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.

Authors:  Werner Poewe; Fabrizio Stocchi; David Arkadir; Georg Ebersbach; Aaron L Ellenbogen; Nir Giladi; Stuart H Isaacson; Karl Kieburtz; Peter LeWitt; C Warren Olanow; Tanya Simuni; Astrid Thomas; Abraham Zlotogorski; Liat Adar; Ryan Case; Sheila Oren; Shir Fuchs Orenbach; Olivia Rosenfeld; Nissim Sasson; Tami Yardeni; Alberto J Espay
Journal:  Mov Disord       Date:  2021-09-08       Impact factor: 9.698

3.  Poisoning by Plants.

Authors:  Sebastian Wendt; Christoph Lübbert; Kathrin Begemann; Dagmar Prasa; Heike Franke
Journal:  Dtsch Arztebl Int       Date:  2022-05-06       Impact factor: 8.251

4.  ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability.

Authors:  Yuval Ramot; Abraham Nyska; Liat Adar; Cecile Durlach; Danny Fishelovitch; Giuseppe Sacco; Rosa Anna Manno; Sheila Oren; Itay Perlstein; Oron Yacobi-Zeevi
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

Review 5.  Cell Death-Autophagy Loop and Glutamate-Glutamine Cycle in Amyotrophic Lateral Sclerosis.

Authors:  Shu Yuan; Zhong-Wei Zhang; Zi-Lin Li
Journal:  Front Mol Neurosci       Date:  2017-07-21       Impact factor: 5.639

6.  A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson's disease.

Authors:  Jayoung Kim; Yongsheng Gao; Zongmin Zhao; Danika Rodrigues; Eden E L Tanner; Kelly Ibsen; Pradip K Sasmal; Rajasekhar Jaladi; Shanavas Alikunju; Samir Mitragotri
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-01       Impact factor: 12.779

Review 7.  Implications of dopaminergic medication withdrawal in Parkinson's disease.

Authors:  J Koschel; K Ray Chaudhuri; L Tönges; M Thiel; V Raeder; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2021-07-29       Impact factor: 3.850

Review 8.  Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy.

Authors:  Robert A Hauser; Santosh Goud; Andrea E Formella
Journal:  Clin Park Relat Disord       Date:  2021-12-08

9.  A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.

Authors:  Eva Thijssen; Jonas den Heijer; David Puibert; Laurence Moss; Mingzu Lei; David Hasegawa; Kyo Keum; Ken Mochel; Mohammed Ezzeldin Sharaf; Tom Alfredson; Wenxiang Zeng; Emilie van Brummelen; Tatjana Naranda; Geert Jan Groeneveld
Journal:  Mov Disord       Date:  2022-01-20       Impact factor: 9.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.